Stratos Wealth Advisors LLC Sells 640 Shares of Johnson & Johnson $JNJ

Stratos Wealth Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 4.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,859 shares of the company’s stock after selling 640 shares during the quarter. Stratos Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $1,964,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in the stock. Sage Private Wealth Group LLC raised its stake in shares of Johnson & Johnson by 13.0% during the 2nd quarter. Sage Private Wealth Group LLC now owns 3,304 shares of the company’s stock valued at $505,000 after purchasing an additional 381 shares during the period. Stratos Investment Management LLC increased its position in shares of Johnson & Johnson by 5.8% during the second quarter. Stratos Investment Management LLC now owns 19,948 shares of the company’s stock valued at $3,047,000 after buying an additional 1,094 shares during the period. Oxbow Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.9% in the second quarter. Oxbow Advisors LLC now owns 44,663 shares of the company’s stock worth $6,822,000 after buying an additional 1,258 shares in the last quarter. Smithbridge Asset Management Inc. DE boosted its position in shares of Johnson & Johnson by 1.7% in the second quarter. Smithbridge Asset Management Inc. DE now owns 41,967 shares of the company’s stock valued at $6,410,000 after acquiring an additional 686 shares during the period. Finally, Commons Capital LLC grew its stake in Johnson & Johnson by 19.0% during the second quarter. Commons Capital LLC now owns 1,826 shares of the company’s stock valued at $279,000 after acquiring an additional 291 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on JNJ shares. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research note on Friday, October 3rd. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Finally, Sanford C. Bernstein lifted their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $199.59.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $193.27 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $465.45 billion, a P/E ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. The stock has a 50-day moving average price of $180.49 and a 200-day moving average price of $164.86. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.40.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion during the quarter. Equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.